AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment

ANGIODYNAMICS INC

2024-FY EPS reported -$4.59 revenue$303,914,000

Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.
Pro forma adjusted net loss improved to $6.5M ($0.16 loss per share) from $5.4M ($0.14 loss) in Feb 2023.
Pro forma net sales for continuing ops were $66.0M, down 6.9% as reported but up 8.0% constant currency vs prior year.
Med Tech segment pro forma sales grew 13.0% to $25.7M; Med Device segment pro forma sales down 14.7% as reported.
Pro forma adjusted EBITDA loss narrowed to $3.6M from $1.5M in the year-ago quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.